Hormonal
Inhibition of miR-103 and miR-107 using the GalNAc-conjugated antagomiR RG-125 (AZD4076) improves hepatic insulin sensitivity and reduces liver triglyceride content in patients with type 2 diabetes or pre-diabetes.
This research highlights a specific pharmaceutical approach (RG-125) targeting liver fat and insulin resistance in diabetic patients. As of the paper's writing, this was in early clinical trials. For now, managing hepatic insulin resistance relies on standard lifestyle interventions (caloric deficit, exercise) and existing medications, keeping an eye on emerging therapies that target specific molecular pathways like miR-103/107.
Treatment with RG-125 (AZD4076) is based on its ability to inhibit the activity of miR-103/107, whose hepatic upregulation causes insulin resistance (Trajkovski et al. 2011). AntagomiR-based silencing of miR-103/107 in mice was followed by decreased liver triglyceride content and improved insulin sensitivity. RG-125 (AZD4076) has therefore the potential to acts as an efficacious insulin sensitizer (RegulusTherapeutics 2015).
Why this rating
The paper is a review summarizing preclinical mouse data and early-phase human trials (Phase I initiated end of 2015); it does not present final efficacy data from large-scale Phase III trials.
Source
Micro<scp>RNA</scp>s in metabolism
Sara G. Vienberg et al. · Acta Physiologica · 2016
DOI 10.1111/apha.12681
More from this paper
- Dysregulation of specific microRNAs (e.g., miR-375, miR-7, miR-200 family, miR-335) in pancreatic beta-cells contributes to impaired insulin secretion and beta-cell failure in Type 2 Diabetes.Good
- Inhibition of liver-specific miR-122 using the antagomiR Miravirsen suppresses Hepatitis C Virus (HCV) replication.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →